Skip to search formSkip to main contentSkip to account menu

ECOG Performance Status 2

Known as: ECOG 2 
Ambulatory and capable of all self care but unable to carry out any work activities. Up and about more than 50% of waking hours.
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2020
Review
2020
Outcomes of curative (chemo)radiotherapy for patients with non‐p16 positive head and neck squamous cell carcinoma who are borderline for curative treatment
Appropriate selection of head and neck squamous cell cancer (HNSCC) patients for curative treatment is difficult, and it is a… 
2020
2020
Definitive re-irradiation of locally recurrent esophageal cancer after trimodality therapy in patients with a poor performance status
There are few treatment guidelines for locally recurrent esophageal cancer after trimodality treatment (pre-operative… 
2018
2018
Outcome following second allogeneic hematopoietic cell transplantation: A single‐center experience
Second allogeneic hematopoietic cell transplantation (HCT) may be indicated following relapse or graft failure following first… 
2015
2015
Predicting Survival After Irradiation for Brain Metastases from Head and Neck Cancer.
AIM Patients with cerebral metastases from head and neck cancer are not common. This study aimed to create an instrument for… 
2014
2014
ERCC1 in Advanced Biliary Tract Cancer Patients Treated with Chemotherapy: Prognostic and Predictive Roles
BackgroundIn oncology, we tend to look for factors that reflect better prognosis or predict response to treatments in order to… 
2014
2014
Regorafenib as a single agent for first-line treatment of frail and/or unfit for polychemotherapy patients with metastatic colorectal cancer (mCRC): A study of the Spanish Cooperative Group for…
3527Background: A 15-20% of pts diagnosed of mCRC do not qualify to receive PChT as first-line therapy, due to age and/or… 
2013
2013
A phase II trial of frontline capecitabine and bevacizumab in poor performance status and/or elderly patients with metastatic colorectal cancer.
2009
2009
Therapy of stage IV B anaplastic thyroid carcinoma: single institution experience.
PURPOSE To evaluate the efficacy of radiotherapy and chemotherapy in stage IV B anaplastic thyroid carcinoma (ATC). PATIENTS… 
2006
2006
A randomized phase II trial with gemcitabine with or without pertuzumab (rhuMAb 2C4) in platinum-resistant ovarian cancer (OC): Preliminary safety data.
13001 Background: Pertuzumab (P), a humanized HER2 antibody, represents a new class of targeted agents called HER dimerization… 
2003
2003
Cisplatin and etoposide alternating ifosfamide, vincristine, epirubicin in small cell lung cancer.
OBJECTIVE The aim of this study was to evaluate the effects and toxicity of alternating cisplatin+etoposide (EP) and ifosfamide… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)